» Articles » PMID: 28163017

Small-Molecule Inhibitors of the SOX18 Transcription Factor

Abstract

Pharmacological modulation of transcription factors (TFs) has only met little success over the past four decades. This is mostly due to standard drug discovery approaches centered on blocking protein/DNA binding or interfering with post-translational modifications. Recent advances in the field of TF biology have revealed a central role of protein-protein interaction in their mode of action. In an attempt to modulate the activity of SOX18 TF, a known regulator of vascular growth in development and disease, we screened a marine extract library for potential small-molecule inhibitors. We identified two compounds, which inspired a series of synthetic SOX18 inhibitors, able to interfere with the SOX18 HMG DNA-binding domain, and to disrupt HMG-dependent protein-protein interaction with RBPJ. These compounds also perturbed SOX18 transcriptional activity in a cell-based reporter gene system. This approach may prove useful in developing a new class of anti-angiogenic compounds based on the inhibition of TF activity.

Citing Articles

Role of the SOX family in cancer immune evasion: Emerging player and promising therapeutic opportunities.

Li J, Xu Y, Han Y, Yang A, Qian M, Wang B Medicine (Baltimore). 2025; 104(5):e41393.

PMID: 39889187 PMC: 11789896. DOI: 10.1097/MD.0000000000041393.


The Transcription Factor SOX18 Inhibitor Small Molecule 4 Is a Potential Treatment of Cancer-Induced Lymphatic Metastasis and Lymphangiosarcoma.

Koll K, Zimmermann M, Will P, Kneser U, Hirche C Cancer Rep (Hoboken). 2025; 8(1):e70110.

PMID: 39791369 PMC: 11726641. DOI: 10.1002/cnr2.70110.


The Activation of the CCND1 Promoter by AP-1 and SOX Transcription Factors in PC3 Prostate Cancer Cells Can Be Prevented by Anacardic Acid Analogs.

Brunie M, Robichaud M, Touaibia M, Martin L Cell Biochem Biophys. 2024; .

PMID: 39729169 DOI: 10.1007/s12013-024-01646-6.


Infantile hemangioma: the common and enigmatic vascular tumor.

Holm A, Mulliken J, Bischoff J J Clin Invest. 2024; 134(8).

PMID: 38618963 PMC: 11014660. DOI: 10.1172/JCI172836.


A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation.

Ralvenius W, Mungenast A, Woolf H, Huston M, Gillingham T, Godin S J Exp Med. 2023; 220(11).

PMID: 37642942 PMC: 10465325. DOI: 10.1084/jem.20222105.